Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Tumor Immunotherapy01:27

Tumor Immunotherapy

575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Cancer Vaccines01:30

Cancer Vaccines

433
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
433
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

837
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
837
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

998
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
998

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Circulation·2026
Same author

Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Neighborhood Socioeconomic Disadvantage and Distance From Treatment Center do not Impact Survival Outcomes of Patients With Non-Hodgkin Lymphoma and Multiple Myeloma Treated With CAR T-Cell Therapies.

Transplantation and cellular therapy·2026
Same author

Step-Specific Activation Timelines for Cellular Therapy Clinical Trials: A Decade of Regulatory Improvement and Persistent Financial Bottlenecks.

Transplantation and cellular therapy·2026
Same author

Immune dysregulation in thymoma: a potential mechanistic link to secondary lung cancer-a case report.

Mediastinum (Hong Kong, China)·2026
Same author

Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck Malignancies.

Cancers·2026

相关实验视频

Updated: Jul 26, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

451

在固体癌症中的T细胞参与者-当前的景观和未来的方向

Mohamed Shanshal1, Paolo F Caimi2, Alex A Adjei2

  • 1Department of Oncology, Mayo Clinic, Rochester, MN 55902, USA.

Cancers
|June 22, 2023
PubMed
概括

双/三特异性抗体技术提供了一个可靠的解决方案.

科学领域:

  • 在瘤学瘤学.
  • 免疫治疗是一种免疫疗法.
  • 制药技术 制药技术 制药技术

背景情况:

  • 单克隆抗体 (例如,针对PD-1,PD-L1,CTLA-4,LAG3) 通过调节抗癌免疫来彻底改变瘤学.
  • 化学抗原受体T细胞 (CAR-T) 疗法提供强大的抗癌免疫力,但面临着重大后勤和资源挑战.
  • 双/三特异性抗体技术提供了一种新的方法,用于激活抗癌效应免疫细胞.

研究的目的:

  • 审查双/三特异性T细胞参与者的新兴领域.
  • 探索这些新型药物的治疗机会.
  • 为了比较向细胞外与细胞内瘤相关抗原 (TAA).

主要方法:

  • 关于双/三特异性抗体技术的综合文献综述.
  • 分析目前的免疫疗法,包括单克隆抗体和CAR-T疗法.
  • 对瘤相关抗原 (TAA) 的向策略的评估.

主要成果:

  • 双/三特异性抗体可以促进效应器免疫细胞的参与,提供"现成"的治疗潜力.
  • 针对细胞外TAA的向可以导致非向毒性.
  • 向细胞内TAA可能会降低非向毒性,同时保持抗瘤功效.
关键词:
这些T细胞参与者.二/三种特异性抗体.固体瘤是一种固体瘤.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

672
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

873

相关实验视频

Last Updated: Jul 26, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:01

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

451
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

672
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

873

结论:

  • 双/三特异性T细胞参与剂代表了癌症免疫疗法的有希望的进步.
  • 使用这些药物向细胞内TAA可能会提高安全性.
  • 这项技术有可能开发出新的,可访问的抗癌疗法.